JP2013507930A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2013507930A5 JP2013507930A5 JP2012534396A JP2012534396A JP2013507930A5 JP 2013507930 A5 JP2013507930 A5 JP 2013507930A5 JP 2012534396 A JP2012534396 A JP 2012534396A JP 2012534396 A JP2012534396 A JP 2012534396A JP 2013507930 A5 JP2013507930 A5 JP 2013507930A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- chimeric
- sequence
- seq
- hfgf19
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US25207409P | 2009-10-15 | 2009-10-15 | |
| US61/252,074 | 2009-10-15 | ||
| PCT/US2010/052852 WO2011047267A1 (en) | 2009-10-15 | 2010-10-15 | Chimeric fibroblast growth factors with altered receptor specificity |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2013507930A JP2013507930A (ja) | 2013-03-07 |
| JP2013507930A5 true JP2013507930A5 (https=) | 2015-07-02 |
| JP6016636B2 JP6016636B2 (ja) | 2016-10-26 |
Family
ID=43876581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012534396A Expired - Fee Related JP6016636B2 (ja) | 2009-10-15 | 2010-10-15 | 改変したレセプター特異性を持つキメラ線維芽細胞増殖因子 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US8535912B2 (https=) |
| EP (1) | EP2488643A4 (https=) |
| JP (1) | JP6016636B2 (https=) |
| KR (1) | KR101952453B1 (https=) |
| CN (1) | CN102656266B (https=) |
| BR (1) | BR112012008907A2 (https=) |
| CA (1) | CA2777717C (https=) |
| MX (2) | MX368790B (https=) |
| RU (1) | RU2573896C2 (https=) |
| WO (1) | WO2011047267A1 (https=) |
Families Citing this family (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2296690B1 (en) | 2008-06-04 | 2016-11-30 | Amgen, Inc | Fgf21 mutants and uses thereof |
| EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| US8324160B2 (en) | 2009-06-17 | 2012-12-04 | Amgen Inc. | Chimeric polypeptides and uses thereof |
| US8889621B2 (en) * | 2009-10-30 | 2014-11-18 | New York University | Inhibiting binding of FGF23 to the binary FGFR-Klotho complex for the treatment of hypophosphatemia |
| CA2796459C (en) | 2010-04-16 | 2016-05-24 | Salk Institute For Biological Studies | Methods for treating metabolic disorders using fgf-1 |
| JP2014500248A (ja) * | 2010-11-05 | 2014-01-09 | コヴェックス・テクノロジーズ・アイルランド・リミテッド | 抗糖尿病化合物 |
| WO2013006486A2 (en) | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| US20130183294A1 (en) * | 2012-01-18 | 2013-07-18 | Genentech, Inc. | Methods of using fgf19 modulators |
| US9475856B2 (en) | 2012-03-02 | 2016-10-25 | New York University | Chimeric FGF21 proteins with enhanced binding affinity for β-klotho for the treatment of type II diabetes, obesity, and related metabolic disorders |
| US9464126B2 (en) * | 2012-06-07 | 2016-10-11 | New York University | Chimeric fibroblast growth factor 21 proteins and methods of use |
| US9657075B2 (en) | 2012-06-07 | 2017-05-23 | New York University | Chimeric fibroblast growth factor 23 proteins and methods of use |
| US9474785B2 (en) | 2012-06-07 | 2016-10-25 | New York University | Chimeric fibroblast growth factor 19 proteins and methods of use |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| HK1214832A1 (zh) | 2012-11-28 | 2016-08-05 | 恩格姆生物制药公司 | 用於代謝病症和疾病治療的組合物和方法 |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| MX383664B (es) * | 2012-12-27 | 2025-03-14 | Ngm Biopharmaceuticals Inc | Uso de un péptido para modular la homeostasis de los ácidos biliares o tratamiento de una enfermedad relacionada con los ácidos biliares. |
| US9550820B2 (en) | 2013-02-22 | 2017-01-24 | New York University | Chimeric fibroblast growth factor 23/fibroblast growth factor 19 proteins and methods of use |
| GB201316592D0 (en) * | 2013-09-18 | 2013-10-30 | Levicept Ltd | Fusion protein |
| AU2014340241B2 (en) | 2013-10-21 | 2018-11-01 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (FGF) 1 and methods of use |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| WO2015065897A1 (en) | 2013-10-28 | 2015-05-07 | Ngm Biopharmaceuticals, Inc. | Cancer models and associated methods |
| PT3097122T (pt) | 2014-01-24 | 2020-07-21 | Ngm Biopharmaceuticals Inc | Anticorpos de ligação de domínio 2 de beta klotho e métodos de utilização dos mesmos |
| CN103816533A (zh) * | 2014-02-27 | 2014-05-28 | 中国药科大学 | Fgf19通过抑制胆汁酸合成发挥抗炎作用的应用 |
| US20170065678A1 (en) | 2014-03-11 | 2017-03-09 | Novartis Ag | Methods of treating metabolic disorders associated with lipodystrophies and defects in insulin production or signaling |
| AU2015237176A1 (en) | 2014-03-28 | 2016-10-20 | New York University | FGF23 fusion proteins |
| WO2015171928A2 (en) * | 2014-05-07 | 2015-11-12 | Joslin Diabetes Center, Inc. | Methods and compositions for induction of ucp1 expression |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| WO2015195509A2 (en) | 2014-06-16 | 2015-12-23 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016048995A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf19 truncations and mutants and uses thereof |
| CN114129709A (zh) | 2014-10-23 | 2022-03-04 | 恩格姆生物制药公司 | 包含肽变异体的药物组合物及其使用方法 |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| EP3108893A1 (en) | 2015-06-25 | 2016-12-28 | Universite Claude Bernard - Lyon 1 | Novel therapeutic use of fgf19 |
| JP6951318B2 (ja) * | 2015-07-15 | 2021-10-20 | プロージット ソウル バイオテクノロジー （ベイジン） カンパニー リミテッド | 融合ポリペプチドおよび使用方法 |
| WO2017019957A2 (en) | 2015-07-29 | 2017-02-02 | Ngm Biopharmaceuticals, Inc. | Binding proteins and methods of use thereof |
| WO2017075260A1 (en) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
| JP6728352B2 (ja) | 2015-11-09 | 2020-07-22 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 胆汁酸に関係した障害の治療方法 |
| WO2017116207A1 (ko) * | 2015-12-31 | 2017-07-06 | 한미약품 주식회사 | Fgf21 아날로그, fgf21 결합체, 및 이의 용도 |
| EP3503882A4 (en) | 2016-08-26 | 2020-07-29 | NGM Biopharmaceuticals, Inc. | METHOD FOR TREATING FIBROBLAST GROWTH FACTOR-19-MEDIATED CARCINOMAS AND TUMORS |
| US12534502B2 (en) * | 2016-10-04 | 2026-01-27 | Svar Life Science Ab | FGF21 responsive reporter gene cell line |
| CN107056925B (zh) * | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
| US20200376080A1 (en) | 2017-12-22 | 2020-12-03 | Novartis Ag | Methods of treating metabolic disorders with fgf21 variants |
| RU2712770C1 (ru) * | 2019-05-21 | 2020-01-31 | Всеволод Викторович Мелехин | Способ ингибирования роста опухолевых клеток |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| WO2021092140A1 (en) * | 2019-11-06 | 2021-05-14 | Ngm Biopharmaceuticals, Inc. | Methods of reducing lactate in liver disease patients using variants and fusions of fgf19/fgf21 polypeptides |
| CN114853869B (zh) * | 2019-12-10 | 2023-12-26 | 湖南赛奥维生物技术有限公司 | 一种碱性成纤维细胞生长因子替代物及其组合物和应用 |
| CN112972654B (zh) * | 2021-03-05 | 2022-07-01 | 温州医科大学慈溪生物医药研究院 | Fgf21在制备治疗脑神经损伤的药物中的应用 |
| CN116284327A (zh) * | 2023-03-28 | 2023-06-23 | 中国药科大学 | 一种靶向肿瘤的成纤维细胞生长因子19的重组蛋白及其应用 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4275149A (en) | 1978-11-24 | 1981-06-23 | Syva Company | Macromolecular environment control in specific receptor assays |
| US4657760A (en) | 1979-03-20 | 1987-04-14 | Ortho Pharmaceutical Corporation | Methods and compositions using monoclonal antibody to human T cells |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| ZA811368B (en) | 1980-03-24 | 1982-04-28 | Genentech Inc | Bacterial polypedtide expression employing tryptophan promoter-operator |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| NZ201705A (en) | 1981-08-31 | 1986-03-14 | Genentech Inc | Recombinant dna method for production of hepatitis b surface antigen in yeast |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| US4943529A (en) | 1982-05-19 | 1990-07-24 | Gist-Brocades Nv | Kluyveromyces as a host strain |
| AU2353384A (en) | 1983-01-19 | 1984-07-26 | Genentech Inc. | Amplification in eukaryotic host cells |
| US4713339A (en) | 1983-01-19 | 1987-12-15 | Genentech, Inc. | Polycistronic expression vector construction |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| AU3145184A (en) | 1983-08-16 | 1985-02-21 | Zymogenetics Inc. | High expression of foreign genes in schizosaccharomyces pombe |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| US4879231A (en) | 1984-10-30 | 1989-11-07 | Phillips Petroleum Company | Transformation of yeasts of the genus pichia |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US5206344A (en) | 1985-06-26 | 1993-04-27 | Cetus Oncology Corporation | Interleukin-2 muteins and polymer conjugation thereof |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| AU597574B2 (en) | 1986-03-07 | 1990-06-07 | Massachusetts Institute Of Technology | Method for enhancing glycoprotein stability |
| GB8610600D0 (en) | 1986-04-30 | 1986-06-04 | Novo Industri As | Transformation of trichoderma |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| US4946783A (en) | 1987-01-30 | 1990-08-07 | President And Fellows Of Harvard College | Periplasmic protease mutants of Escherichia coli |
| US5010182A (en) | 1987-07-28 | 1991-04-23 | Chiron Corporation | DNA constructs containing a Kluyveromyces alpha factor leader sequence for directing secretion of heterologous polypeptides |
| DE3850542T2 (de) | 1987-09-23 | 1994-11-24 | Bristol Myers Squibb Co | Antikörper-Heterokonjugate zur Töting von HIV-infizierten Zellen. |
| GB8724885D0 (en) | 1987-10-23 | 1987-11-25 | Binns M M | Fowlpox virus promotors |
| ATE105585T1 (de) | 1987-12-21 | 1994-05-15 | Univ Toledo | Transformation von keimenden pflanzensamen mit hilfe von agrobacterium. |
| AU4005289A (en) | 1988-08-25 | 1990-03-01 | Smithkline Beecham Corporation | Recombinant saccharomyces |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5225538A (en) | 1989-02-23 | 1993-07-06 | Genentech, Inc. | Lymphocyte homing receptor/immunoglobulin fusion proteins |
| US5009772A (en) | 1989-02-27 | 1991-04-23 | Kerr-Mcgee Corporation | Solvent extraction process |
| EP0462145B1 (en) | 1989-03-07 | 1994-04-27 | Genentech, Inc. | Covalent conjugates of lipid and oligonucleotide |
| ATE144281T1 (de) | 1989-04-28 | 1996-11-15 | Rhein Biotech Proz & Prod Gmbh | Hefezellen der gattung-schwanniomyces |
| FR2646437B1 (fr) | 1989-04-28 | 1991-08-30 | Transgene Sa | Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant |
| WO1990013641A1 (en) | 1989-05-10 | 1990-11-15 | Sloan-Kettering Institute For Cancer Research | Stably transformed eucaryotic cells comprising a foreign transcribable dna under the control of a pol iii promoter |
| EP0402226A1 (en) | 1989-06-06 | 1990-12-12 | Institut National De La Recherche Agronomique | Transformation vectors for yeast yarrowia |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| ES2096590T3 (es) | 1989-06-29 | 1997-03-16 | Medarex Inc | Reactivos biespecificos para la terapia del sida. |
| FR2649120B1 (fr) | 1989-06-30 | 1994-01-28 | Cayla | Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede |
| US5225212A (en) | 1989-10-20 | 1993-07-06 | Liposome Technology, Inc. | Microreservoir liposome composition and method |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| WO1991006629A1 (en) | 1989-10-24 | 1991-05-16 | Gilead Sciences, Inc. | Oligonucleotide analogs with novel linkages |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| ATE300615T1 (de) | 1990-08-29 | 2005-08-15 | Genpharm Int | Transgene mäuse fähig zur produktion heterologer antikörper |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5206161A (en) | 1991-02-01 | 1993-04-27 | Genentech, Inc. | Human plasma carboxypeptidase B |
| EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| DE69232137T2 (de) | 1991-11-25 | 2002-05-29 | Enzon Inc | Multivalente antigen-bindende proteine |
| MD1367C2 (ro) | 1992-11-13 | 2000-11-30 | Idec Pharmaceuticals Corporation | Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom. |
| WO1994012158A1 (en) | 1992-12-02 | 1994-06-09 | Alkermes Controlled Therapeutics, Inc. | Controlled release growth hormone containing microspheres |
| DK0779806T3 (da) | 1994-09-09 | 2000-11-27 | Takeda Chemical Industries Ltd | Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| NZ310644A (en) | 1995-06-07 | 1999-08-30 | Alkermes Inc | Composition for sustained release of human growth hormone |
| ZA965368B (en) | 1995-07-14 | 1997-01-14 | Novo Nordisk As | A pharmaceutical formulation |
| EP1032668B1 (en) * | 1997-11-25 | 2008-05-28 | Genentech, Inc. | Fibroblast growth factor-19 |
| US20040126852A1 (en) * | 1997-11-25 | 2004-07-01 | Genentech, Inc. | Fibroblast growth factor-19 (FGF-19) nucleic acids and polypeptides and methods of use for the treatment of obesity |
| US7829693B2 (en) * | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| AU2004244756A1 (en) * | 2003-06-05 | 2004-12-16 | Centelion | Plasmid encoding fibroblast growth factor for the treatment of hypercholesterolemia or diabetes associated angiogenic defects |
| SI1751184T1 (sl) * | 2004-05-13 | 2010-01-29 | Lilly Co Eli | Fgf-21 fuzijski proteini |
| EP1989230B1 (en) * | 2006-02-10 | 2016-06-01 | Genentech, Inc. | Anti-fgf19 antibodies and methods using same |
| BRPI0812384A2 (pt) * | 2007-05-22 | 2014-12-02 | Novartis Ag | Métodos de tratamento, diagnóstico e detecção de distúrbios associados a fgf21 |
| TW200936156A (en) * | 2008-01-28 | 2009-09-01 | Novartis Ag | Methods and compositions using Klotho-FGF fusion polypeptides |
| US8324160B2 (en) | 2009-06-17 | 2012-12-04 | Amgen Inc. | Chimeric polypeptides and uses thereof |
| WO2013006486A2 (en) * | 2011-07-01 | 2013-01-10 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
-
2010
- 2010-10-15 MX MX2015013444A patent/MX368790B/es unknown
- 2010-10-15 EP EP20100824168 patent/EP2488643A4/en not_active Ceased
- 2010-10-15 MX MX2012004303A patent/MX2012004303A/es not_active Application Discontinuation
- 2010-10-15 CN CN201080046715.0A patent/CN102656266B/zh not_active Expired - Fee Related
- 2010-10-15 RU RU2012119800/10A patent/RU2573896C2/ru active
- 2010-10-15 KR KR1020127012353A patent/KR101952453B1/ko not_active Expired - Fee Related
- 2010-10-15 JP JP2012534396A patent/JP6016636B2/ja not_active Expired - Fee Related
- 2010-10-15 CA CA2777717A patent/CA2777717C/en active Active
- 2010-10-15 US US12/905,776 patent/US8535912B2/en not_active Expired - Fee Related
- 2010-10-15 BR BR112012008907-2A patent/BR112012008907A2/pt not_active Application Discontinuation
- 2010-10-15 WO PCT/US2010/052852 patent/WO2011047267A1/en not_active Ceased
-
2013
- 2013-08-07 US US13/961,766 patent/US20140148388A1/en not_active Abandoned
-
2017
- 2017-08-03 US US15/668,573 patent/US20180079806A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2013507930A5 (https=) | ||
| JP7635291B2 (ja) | 組織特異的Ｗｎｔシグナル増強分子およびその使用 | |
| RU2012119800A (ru) | Химерные факторы роста фибробластов с измененной рецепторной специфичностью | |
| US9493530B2 (en) | FGF21 mutants comprising a mutation at position 98, 171 and/or 180 | |
| CN101993496B (zh) | 双重调节血糖血脂融合蛋白及其制法和用途 | |
| TWI708782B (zh) | 新穎胰島素類似物及其用途 | |
| AU2014296107B2 (en) | Growth differentiation factor 15 (GDF-15) constructs | |
| CN101679988B (zh) | 结合生长因子的融合蛋白 | |
| KR20230029622A (ko) | April 및 baff 억제 면역조절 단백질 및 사용 방법 | |
| CA3223591A1 (en) | Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (gipr) in combination with glp-1 agonists | |
| JP2017529059A5 (https=) | ||
| CN108350054A (zh) | 双功能蛋白质和包含其的药物组合物 | |
| JP2014508510A5 (https=) | ||
| HU230603B1 (hu) | GLP1 fúziós fehérjék | |
| JP2009513162A5 (https=) | ||
| HRP20170323T1 (hr) | Dopunski aktivin receptor polipeptidi i njihove upotrebe | |
| JP2008526233A (ja) | Ｉｇｆ−ｉ融合ポリペプチドの組み合わせ治療用物質による肥満治療法 | |
| CN114591415B (zh) | Glp-1/gcg双受体激动剂多肽及其融合蛋白 | |
| CN116916947A (zh) | 包含磺基葡糖胺磺基水解酶的融合蛋白和其方法 | |
| CN113105561B (zh) | 一种双靶点融合蛋白的制备方法和应用 | |
| JP6320973B2 (ja) | Ｂ細胞活性化因子の拮抗物質、その調製方法及び利用法 | |
| CN106279430B (zh) | Exendin‑4类似物融合蛋白及其制备方法和用途 | |
| JPWO2021229076A5 (https=) | ||
| CA3238005A1 (en) | Chimeric antigen receptors | |
| WO2018188179A1 (zh) | 胰高血糖素样肽-1受体激动剂融合蛋白及其应用 |